# Immunoglobulin Replacement Therapy

## Indications

### Primary Immunodeficiency

Immunoglobulin replacement therapy is the cornerstone of treatment for primary immunodeficiency disorders characterized by deficient antibody production. X-linked agammaglobulinemia (XLA), in which B cell development is arrested at the pre-B cell stage due to Bruton tyrosine kinase mutations, represents the prototypical indication, as these patients produce essentially no immunoglobulin of any class. Common variable immunodeficiency (CVID), the most prevalent symptomatic primary immunodeficiency, is another major indication, as the majority of CVID patients have significantly reduced IgG levels with impaired specific antibody responses. Hyper-IgM syndromes, whether due to CD40 ligand deficiency (X-linked) or activation-induced cytidine deaminase (AID) deficiency, result in an inability to undergo class switch recombination, leaving patients with absent or profoundly reduced IgG, IgA, and IgE despite normal or elevated IgM levels. Severe combined immunodeficiency (SCID) patients require immunoglobulin replacement as a bridge to definitive therapy with hematopoietic stem cell transplantation. Wiskott-Aldrich syndrome, with its characteristic triad of thrombocytopenia, eczema, and immunodeficiency, often necessitates IgG replacement due to impaired antibody responses, particularly to polysaccharide antigens.

Beyond these classic indications, specific antibody deficiency -- defined as failure to mount adequate antibody responses to polysaccharide vaccine antigens despite normal quantitative immunoglobulin levels -- may warrant replacement therapy when patients experience recurrent infections despite vaccination attempts. Similarly, IgG subclass deficiency with documented specific antibody failure and recurrent infections may be an appropriate indication. Other primary immunodeficiency disorders with demonstrated antibody deficiency are evaluated on a case-by-case basis.

### Secondary Immunodeficiency (Select Cases)

Secondary hypogammaglobulinemia from hematologic malignancies and their treatments represents an increasingly recognized indication for immunoglobulin replacement. Chronic lymphocytic leukemia (CLL) is the most common cause of secondary hypogammaglobulinemia, and patients with recurrent infections and low IgG levels benefit from replacement therapy. Multiple myeloma, despite the overproduction of monoclonal immunoglobulin, is associated with suppression of uninvolved immunoglobulins (immunoparesis), and patients with secondary hypogammaglobulinemia and recurrent infections may require replacement. Post-hematopoietic stem cell transplantation hypogammaglobulinemia is another established indication. Rituximab, widely used across hematologic and autoimmune conditions, can produce prolonged hypogammaglobulinemia that persists well beyond B cell recovery, and affected patients with recurrent infections benefit from IgG replacement. HIV-associated hypogammaglobulinemia in children was historically an important indication, though this has become less common with the widespread availability of antiretroviral therapy.

### High-Dose IVIG for Immunomodulation (Different Indication/Mechanism)

It is important to distinguish replacement-dose immunoglobulin therapy from high-dose intravenous immunoglobulin (IVIG) used for its immunomodulatory properties, as these represent fundamentally different therapeutic applications with distinct dosing regimens and mechanisms. Immune thrombocytopenia (ITP) is treated with IVIG at 1 to 2 grams per kilogram to rapidly raise platelet counts through blockade of Fc receptors on splenic macrophages. Kawasaki disease requires a single dose of 2 grams per kilogram to reduce the incidence of coronary artery aneurysms. Guillain-Barre syndrome is treated with 0.4 grams per kilogram per day for five days. Chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, and dermatomyositis are additional neurologic and rheumatologic conditions for which immunomodulatory IVIG has demonstrated efficacy.

The immunomodulatory mechanisms of high-dose IVIG are multifaceted and include upregulation of the inhibitory Fc receptor FcgammaRIIB on effector macrophages, provision of anti-idiotypic antibodies that neutralize pathogenic autoantibodies, scavenging of activated complement components, modulation of cytokine networks, and saturation of the neonatal Fc receptor (FcRn), which increases the catabolic rate of all IgG including pathogenic autoantibodies.

## Product Types

### Intravenous Immunoglobulin (IVIG)

Intravenous immunoglobulin products are manufactured from pooled plasma collected from 1,000 to 60,000 donors per production lot, providing a broad repertoire of antibody specificities reflecting the collective immune experience of the donor population. The final product consists of greater than 95% IgG, with trace amounts of IgA (which varies by product and is clinically relevant for IgA-deficient patients) and minimal IgM. The IgG subclass distribution approximately mirrors that of normal serum, with IgG1 comprising 60 to 70%, IgG2 at 20 to 30%, and smaller proportions of IgG3 and IgG4.

Multiple IVIG products are available on the market, including Gammagard Liquid, Gammaked, Gamunex-C, Privigen, Octagam, Panzyga, Bivigam, and Asceniv. While all are manufactured from pooled human plasma and contain predominantly IgG, they differ in their manufacturing processes, stabilizers, IgA content, pH, osmolality, and sugar content, which can influence tolerability in individual patients. IVIG is administered as an intravenous infusion every three to four weeks at a typical replacement dose of 400 to 600 mg/kg/month. Infusions are initiated at a slow rate (0.5 to 1 mL/kg/hr) and titrated upward to a maximum rate of 4 to 8 mL/kg/hr depending on the specific product and patient tolerance, with total infusion durations ranging from two to six hours.

### Comparison of Immunoglobulin Delivery Routes

| Feature | IVIG | SCIG | fSCIG (HyQvia) |
|---|---|---|---|
| Route | Intravenous | Subcutaneous | Subcutaneous + hyaluronidase |
| Frequency | Every 3-4 weeks | Weekly or biweekly | Monthly |
| Infusion duration | 2-6 hours | 1-2 hours | 2-4 hours |
| Setting | Clinic/infusion center | Home (self-administered) | Home (self-administered) |
| Infusion sites | Single IV access | Multiple sites (abdomen, thighs, arms) | Single site (up to 600 mL) |
| IgG level profile | Peak-and-trough fluctuation | Steady-state (minimal fluctuation) | Moderate peak-trough |
| Systemic reaction rate | 5-15% | <1% | ~3% |
| Local site reactions | Rare | ~75% initially (declines to ~25%) | Moderate |
| Volume per site | N/A | 15-25 mL/site | Up to 600 mL/site |

### Subcutaneous Immunoglobulin (SCIG)

Subcutaneous immunoglobulin preparations utilize the same IgG source material adapted for subcutaneous delivery. Available products include Hizentra (20% concentration), Cuvitru (20%), Gammagard S/C (10%), Cutaquig (16.5%), and Xembify (20%). SCIG is typically administered as weekly or biweekly self-infusions at home after appropriate patient training. The total monthly dose is equivalent to the IVIG dose but divided into weekly aliquots, adjusted per product-specific labeling. Infusion sites include the abdomen, thighs, and upper arms, with rotation among sites recommended, and multiple simultaneous infusion sites are often necessary to deliver the required volume.

The pharmacokinetic advantages of SCIG are significant. Because immunoglobulin is absorbed gradually from the subcutaneous space, serum IgG levels remain remarkably steady without the pronounced peak-and-trough fluctuations characteristic of monthly IVIG infusions. This steady-state profile may contribute to a reduction in systemic adverse effects, as the rate of systemic reactions with SCIG is less than 1%, substantially lower than the 5 to 15% rate observed with IVIG. Additional advantages include the convenience and autonomy of home-based self-administration. The principal disadvantages include local injection site reactions (erythema, swelling, and induration), the need for more frequent infusions, and volume limitations at each injection site.

### Facilitated Subcutaneous (fSCIG)

Hyaluronidase-facilitated subcutaneous immunoglobulin (HyQvia) represents an innovative approach that combines recombinant human hyaluronidase (rHuPH20) with a 10% IgG solution. The hyaluronidase enzyme temporarily increases the permeability of the subcutaneous tissue by depolymerizing hyaluronic acid in the extracellular matrix, allowing much larger volumes of immunoglobulin to be infused per site -- up to 600 mL at a single infusion site. This permits monthly dosing intervals comparable to IVIG, while retaining the benefits of subcutaneous delivery including home administration and a favorable safety profile. The treatment is administered at a single infusion site per session, and patients can self-administer at home after appropriate training. HyQvia thus combines the scheduling convenience of monthly IVIG with the home-based delivery and improved tolerability profile of subcutaneous administration.

<image>A comparison infographic of IVIG versus SCIG versus fSCIG administration. Three panels: (1) IVIG: illustration of IV infusion setup in clinic/infusion center, showing IV bag, drip chamber, and arm with IV access. Graph below showing serum IgG level over 4 weeks with high peak after infusion, then declining trough before next infusion. Stats: infusion every 3-4 weeks, 2-6 hour infusion, in-clinic. (2) SCIG: illustration of patient at home using SC infusion pump with multiple abdominal sites, butterfly needle sets. Graph showing steady-state IgG levels with minimal fluctuation throughout the week. Stats: weekly infusion, 1-2 hours, home-based, multiple sites (15-25 mL/site). (3) fSCIG (HyQvia): illustration showing hyaluronidase injection first, then IgG infusion at single site, home-based. Graph showing monthly dosing with moderate peak-trough (less than IVIG). Stats: monthly, single site, up to 600 mL/site, home-based after training. Bottom comparison table: systemic reaction rate (IVIG > fSCIG > SCIG), local reactions (SCIG/fSCIG > IVIG), convenience, steady-state levels.</image>

## Dosing and Monitoring

### Initial Dosing

The standard replacement dose for primary and secondary immunodeficiency is 400 to 600 mg/kg/month. Most clinicians initiate therapy at 400 mg/kg/month and adjust upward based on clinical response and trough levels. Some patients, particularly those with established bronchiectasis, chronic sinusitis, or persistent infections on standard dosing, may require higher doses of up to 800 mg/kg/month to achieve optimal infection prevention. In patients presenting with very low serum IgG levels (below 200 mg/dL), a loading dose may be administered to more rapidly achieve protective levels, though this should be infused cautiously as the risk of adverse reactions may be higher in immunoglobulin-naive patients.

### Trough Level Monitoring

Trough IgG levels should be measured just before the next scheduled IVIG infusion to capture the nadir serum concentration. For patients on SCIG, levels can be drawn at any time since subcutaneous administration produces essentially steady-state kinetics. The general target trough is at least 500 mg/dL, though many experts recommend targeting 700 to 800 mg/dL or higher based on evidence that higher trough levels are associated with fewer infections, particularly pneumonia.

The concept of the "biologic trough" acknowledges that individual patients have different optimal trough levels that may differ substantially from population-based targets. Some patients remain infection-free at trough levels of 500 mg/dL, while others continue to experience recurrent infections until their trough exceeds 1,000 mg/dL. Therefore, dose adjustment should be guided primarily by clinical response -- specifically the frequency and severity of infections -- rather than by adherence to an arbitrary trough target. Steady-state trough levels are typically achieved after three to five half-lives of IgG, which corresponds to approximately three to four months of regular dosing. The half-life of infused IgG is approximately 21 to 35 days, varying by product and individual patient factors, and is dependent on FcRn-mediated recycling.

### Monitoring Protocol

Prior to each infusion, vital signs should be recorded and the patient should be assessed for interval infections or other clinical changes. Trough IgG levels should be checked every three to six months during the initial dosing optimization phase, then annually once stable. Annual laboratory monitoring should include a complete blood count, comprehensive metabolic panel with particular attention to renal function, liver function tests, and hepatitis serologies at baseline. Given the progressive nature of lung disease in many antibody-deficient patients, annual pulmonary function testing and a baseline high-resolution CT of the chest to assess for bronchiectasis are recommended. Patients should also be monitored for the development of autoimmune complications, which are common in disorders such as CVID.

## Adverse Effects

### Summary of IVIG Adverse Effects

| Adverse Effect | Timing | Frequency | Risk Factors | Management |
|---|---|---|---|---|
| Infusion-related reactions (headache, chills, flushing) | During infusion | 5-15% | First infusion, product switch, prolonged interval | Slow/stop infusion; premedicate with acetaminophen, diphenhydramine |
| Anaphylaxis | During infusion | Rare | IgA deficiency with anti-IgA IgE antibodies | Epinephrine; use IgA-depleted products if confirmed |
| Aseptic meningitis | 24-72 hours post-infusion | Uncommon | High-dose immunomodulatory IVIG | Supportive care; self-limited |
| Renal dysfunction (osmotic nephropathy) | Days post-infusion | Uncommon | Pre-existing renal disease, diabetes, sucrose-containing products | Hydration; avoid sucrose-containing products |
| Thrombotic events (stroke, MI, PE, DVT) | During or post-infusion | Rare | Age, immobility, hypercoagulable states, CV risk factors | Adequate hydration; slow infusion rate |
| Hemolytic anemia | Days post-infusion | Uncommon | Non-O blood type; high-dose IVIG | Monitor DAT, Hgb, reticulocytes, LDH, haptoglobin |
| TRALI | During or shortly after infusion | Rare | Donor antibodies | Supportive care; report to blood bank |

### IVIG-Specific

Infusion-related reactions occur in approximately 5 to 15% of IVIG infusions and represent the most common adverse effect. These reactions typically manifest as headache (the single most frequent symptom), myalgia, chills, fever, nausea, and flushing. They are usually rate-related and respond to slowing or temporarily stopping the infusion. Premedication with acetaminophen, diphenhydramine, and in some cases low-dose hydrocortisone can mitigate these reactions. Infusion reactions are more common during the first infusion in a treatment-naive patient, after switching between products, or when there has been a prolonged interval between infusions.

True anaphylaxis to IVIG is rare but carries heightened risk in IgA-deficient patients who have developed anti-IgA antibodies, particularly anti-IgA IgE antibodies. Historically, IgA-depleted products such as Gammagard S/D were used for such patients, though most modern IVIG preparations contain very low levels of IgA, and true IgA-mediated anaphylaxis remains exceedingly uncommon.

Aseptic meningitis is a recognized complication characterized by severe headache, photophobia, and meningismus developing 24 to 72 hours post-infusion. Cerebrospinal fluid analysis reveals a lymphocytic pleocytosis without organisms, confirming the sterile inflammatory nature of the condition. This complication is more frequently observed with the high doses used for immunomodulatory indications than with replacement dosing.

Renal dysfunction, specifically osmotic nephropathy, has been associated with IVIG administration. Risk factors include pre-existing renal disease, diabetes mellitus, dehydration, and concurrent use of nephrotoxic medications. Products containing sucrose as a stabilizer were historically associated with the highest risk of renal injury, and most such products have been discontinued or reformulated.

Thrombotic events including stroke, myocardial infarction, pulmonary embolism, and deep vein thrombosis are a serious concern, particularly in patients with advanced age, immobilization, hypercoagulable states, or cardiovascular risk factors. Adequate hydration before and during the infusion is critical for risk mitigation. The thrombotic risk is thought to relate to the presence of procoagulant factors and activated clotting factors in some IVIG preparations, as well as hyperviscosity from the infused protein load.

Hemolytic anemia results from anti-A and anti-B isohemagglutinins present in pooled IVIG that can bind to recipient red blood cells in patients with non-O blood types. This passive hemolysis is more common with high-dose immunomodulatory IVIG than with replacement dosing. Monitoring should include direct antiglobulin testing (Coombs test), hemoglobin, reticulocyte count, lactate dehydrogenase, and haptoglobin levels. Transfusion-related acute lung injury (TRALI), while rare, is a serious and potentially fatal complication that must be recognized and managed promptly.

### SCIG-Specific

Local injection site reactions are the most common adverse effect of subcutaneous immunoglobulin, occurring in approximately 75% of patients during the first month of therapy. These reactions manifest as erythema, swelling, induration, and pruritus at the injection sites. They are generally mild and self-limited, and importantly, they tend to diminish significantly with continued treatment, declining to approximately 25% with ongoing use. Systemic reactions with SCIG are much less common than with IVIG, occurring in less than 1% of infusions, which represents one of the major safety advantages of the subcutaneous route.

## Special Considerations

### IgA Deficiency and Ig Replacement

A common clinical concern is the safety of immunoglobulin administration in IgA-deficient patients. In practice, the vast majority of IgA-deficient patients tolerate standard IgG preparations without difficulty, as IgA is present only in trace amounts in these products. True anti-IgA IgE antibodies, which would mediate anaphylaxis, are extremely rare. When a patient with known IgA deficiency has a documented history of anaphylaxis to blood products, anti-IgA antibody levels should be measured. The IgA content of commonly used immunoglobulin products is generally below 50 micrograms per milliliter, which is well below the threshold likely to trigger reactions in most sensitized patients.

### Vaccination During Ig Replacement

The interaction between passive immunoglobulin replacement and active vaccination requires careful consideration. Live vaccines are generally contraindicated in patients receiving immunoglobulin replacement because the passively administered IgG may contain neutralizing antibodies against live vaccine viruses, preventing successful immunization. Guidelines recommend waiting at least three months after the last IVIG dose before administering live vaccines, with longer intervals of 8 to 11 months recommended for measles and varicella vaccines depending on the dose received. In practice, patients on chronic immunoglobulin replacement rarely receive live vaccines, as most have underlying immunodeficiency disorders that independently contraindicate live vaccination.

Inactivated vaccines can be administered during immunoglobulin replacement therapy, though the antibody response may be blunted by the presence of passively administered antibodies. Annual influenza vaccination is still recommended, as some protective response is expected. COVID-19 mRNA vaccines should be administered to eligible patients, though the optimal timing relative to IVIG infusions has not been clearly established to affect response.

### Pregnancy

Immunoglobulin G crosses the placenta via FcRn-mediated transcytosis, and IVIG or SCIG therapy is considered safe during pregnancy. The therapeutic IgG provides passive protection for both the mother and developing fetus. Dose adjustments may be necessary as pregnancy progresses due to the expansion of blood volume, which can dilute serum IgG concentrations. Continuation of replacement therapy throughout pregnancy is important to maintain maternal and fetal protection.

### Product Switching

Immunoglobulin products are not considered interchangeable, as they differ in their formulations, stabilizers, IgA content, osmolality, pH, and concentration. When switching between products, adjustments to the infusion rate and premedication regimen may be necessary, and patients should be monitored for new infusion reactions that may not have occurred with the prior product. The same monthly dose in milligrams per kilogram should be maintained when switching.

<image>An adverse effects monitoring chart for immunoglobulin replacement therapy. Organized as a timeline showing when different adverse effects occur relative to the infusion. During infusion (0-4 hours): rate-related reactions (headache, chills, flushing - shown with decreasing infusion rate icon), anaphylaxis (rare, shown with epinephrine syringe). Early post-infusion (24-72 hours): aseptic meningitis (headache, photophobia), hemolytic anemia (DAT positive, dropping Hgb). Late effects (days to weeks): renal dysfunction (rising creatinine), thrombotic events (stroke, PE - with risk factors listed). For each adverse effect, show: frequency, risk factors, prevention strategies, and management. Bottom panel: monitoring schedule showing baseline labs, trough IgG timing, and annual assessments (PFTs, CT chest, CBC, CMP).</image>

## Key Clinical Pearls

- Target IgG trough levels should be individualized; clinical response (infection frequency) is more important than a specific trough number
- SCIG provides more stable IgG levels with fewer systemic reactions than IVIG; particularly beneficial for patients with frequent infusion reactions
- HyQvia (fSCIG) combines the monthly dosing convenience of IVIG with the safety profile and home administration of SCIG
- Hydration before and during IVIG reduces risk of renal dysfunction and thrombotic events; slow initial infusion rate reduces infusion reactions
- Hemolytic anemia from IVIG is due to anti-A/anti-B isohemagglutinins; monitor non-type-O patients receiving high-dose immunomodulatory IVIG
- IgA-deficient patients very rarely have true anti-IgA IgE antibodies; most tolerate standard IgG products
- Live vaccines should be avoided during Ig replacement therapy; administer inactivated vaccines regardless of IgG replacement
- Ig replacement does not correct other immune defects (T cell, phagocyte); patients may need additional antimicrobial prophylaxis depending on their underlying PID

## References
1. Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. *Allergy Asthma Proc*. 2016;37(6):426-431.
2. Perez EE, et al. Update on the use of immunoglobulin in human disease: a review of evidence. *J Allergy Clin Immunol*. 2017;139(3S):S1-S46.
3. Wasserman RL, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. *J Allergy Clin Immunol*. 2012;130(4):951-957.
4. Orange JS, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the AAAAI. *J Allergy Clin Immunol*. 2006;117(4 Suppl):S525-S553.
5. Sriaroon P, Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency. *Immunol Allergy Clin North Am*. 2015;35(4):713-730.